Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 729017, 8 pages
http://dx.doi.org/10.1155/2015/729017
Research Article

Polydatin Inhibits Formation of Macrophage-Derived Foam Cells

1Department of Cardiovascular Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
2Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
3Qilu Hospital of Shandong University, Jinan 250012, China
4Shandong University of Traditional Chinese Medicine, Shandong 250355, China

Received 1 March 2015; Accepted 4 May 2015

Academic Editor: Dan Hu

Copyright © 2015 Min Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. C. K. Glass and J. L. Witztum, “Atherosclerosis: the road ahead,” Cell, vol. 104, no. 4, pp. 503–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Gui, A. Shimokado, Y. Sun, T. Akasaka, and Y. Muragaki, “Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery,” Mediators of Inflammation, vol. 2012, Article ID 693083, 14 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Yuan, P. Li, and J. Ye, “Lipid homeostasis and the formation of macrophage-derived foam cells in atherosclerosis,” Protein & Cell, vol. 3, no. 3, pp. 173–181, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Persson, J. Nilsson, and M. W. Lindholm, “Cytokine response to lipoprotein lipid loading in human monocyte-derived macrophages,” Lipids in Health and Disease, vol. 5, article 17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. P. Choudhury, J. M. Lee, and D. R. Greaves, “Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis,” Nature Clinical Practice Cardiovascular Medicine, vol. 2, no. 6, pp. 309–315, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Febbraio, D. P. Hajjar, and R. L. Silverstein, “CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism,” Journal of Clinical Investigation, vol. 108, no. 6, pp. 785–791, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. V. V. Kunjathoor, M. Febbraio, E. A. Podrez et al., “Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49982–49988, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. S. O. Rahaman, D. J. Lennon, M. Febbraio, E. A. Podrez, S. L. Hazen, and R. Silverstein, “A CD36-dependent signaling cascade is necessary for macrophage foam cell formation,” Cell Metabolism, vol. 4, no. 3, pp. 211–221, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Febbraio, E. A. Podrez, J. D. Smith et al., “Targeted disruption of the class B, scavenger receptor CD36 protects against atherosclerotic lesion development in mice,” Journal of Clinical Investigation, vol. 105, no. 8, pp. 1049–1056, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Wang, D. L. Silver, C. Thiele, and A. R. Tall, “ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein,” The Journal of Biological Chemistry, vol. 276, no. 26, pp. 23742–23747, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Li, D. Wang, Y. Wang, W. Ling, X. Feng, and M. Xia, “Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice,” The Journal of Biological Chemistry, vol. 285, no. 43, pp. 33499–33509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. C. Li, C. J. Binder, A. Gutierrez et al., “Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma,” The Journal of Clinical Investigation, vol. 114, no. 11, pp. 1564–1576, 2004. View at Google Scholar
  15. A. Castrillo and P. Tontonoz, “PPARs in atherosclerosis: the clot thickens,” The Journal of Clinical Investigation, vol. 114, no. 11, pp. 1538–1540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Chinetti, S. Lestavel, V. Bocher et al., “PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway,” Nature Medicine, vol. 7, no. 1, pp. 53–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. T. E. Akiyama, S. Sakai, G. Lambert et al., “Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux,” Molecular and Cellular Biology, vol. 22, no. 8, pp. 2607–2619, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. X. H. Kong and L. Z. Zhou, “Study progress of glant knotweed rhizome,” Guiding Journal of Traditional Chinese Medicine and Pharmacy, vol. 15, no. 5, pp. 107–110, 2009. View at Google Scholar
  20. L.-T. Liu, G. Guo, M. Wu, and W.-G. Zhang, “The progress of the research on cardio-vascular effects and acting mechanism of polydatin,” Chinese Journal of Integrative Medicine, vol. 18, no. 9, pp. 714–719, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Ogawa, S. Nakamura, Y. Saito, M. Kosugi, and Y. Magata, “What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 55–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Xu, Y. Huang, Y. Xie et al., “Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake,” Cytotechnology, vol. 62, no. 5, pp. 473–481, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K.-Y. Lu, L.-C. Ching, K.-H. Su et al., “Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor α,” Circulation, vol. 121, no. 16, pp. 1828–1837, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ditiatkovski, B.-H. Toh, and A. Bobik, “GM-CSF deficiency reduces macrophage PPAR-γ expression and aggravates atherosclerosis in ApoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 10, pp. 2337–2344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. A. Berliner, M. Navab, A. M. Fogelman et al., “Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics,” Circulation, vol. 91, no. 9, pp. 2488–2496, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Aviram, “Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 34, no. 8, pp. 599–608, 1996. View at Google Scholar · View at Scopus
  27. D. Steinberg, “Low density lipoprotein oxidation and its pathobiological significance,” The Journal of Biological Chemistry, vol. 272, no. 34, pp. 20963–20966, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kaplan, T. Hayek, A. Raz et al., “Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis,” Journal of Nutrition, vol. 131, no. 8, pp. 2082–2089, 2001. View at Google Scholar · View at Scopus
  29. J. Tian, X. Gu, Y. Sun et al., “Effect of statin therapy on the progression of coronary atherosclerosis,” BMC Cardiovascular Disorders, vol. 12, article 70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Huang, W. Li, L. Dong, R. Li, and Y. Wu, “Effect of statin therapy on the progression of common carotid artery intima-media thickness: an updated systematic review and meta-analysis of randomized controlled trials,” Journal of Atherosclerosis and Thrombosis, vol. 20, no. 1, pp. 108–121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. O. Hegland, M. W. Kurz, P. S. Munk, and J. P. Larsen, “The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity,” Acta Neurologica Scandinavica, vol. 121, no. 1, pp. 11–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Du, L.-N. Sun, W.-W. Xing et al., “Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters,” Phytomedicine, vol. 16, no. 6-7, pp. 652–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. L. T. Liu, M. Wu, W. G. Zhang et al., “Clinical study on treatment of carotid atherosclerosis with extraction of Polygoni Cuspidati Rhizoma et Radix and Crataegi Fructus: a randomized controlled trial,” China Journal of Chinese Materia Medica, vol. 39, no. 6, pp. 1115–1119, 2014. View at Publisher · View at Google Scholar
  35. L. T. Liu, G. J. Zheng, W. G. Zhang, G. Guo, and M. Wu, “Clinical study on treatment of carotid atherosclerosis with polydatin,” Beijing Journal of Traditional Chinese Medicine, vol. 28, no. 3, pp. 172–175, 2009. View at Google Scholar
  36. S. H. Gao, S. L. Yang, and G. R. Fan, “Study progress of polydatin,” Journal Pharmaceutical Practice, vol. 23, no. 6, pp. 145–147, 2005. View at Google Scholar
  37. S. Das and D. K. Das, “Resveratrol: a therapeutic promise for cardiovascular diseases,” Recent Patents on Cardiovascular Drug Discovery, vol. 2, no. 2, pp. 133–138, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Pataki, G. Lusztig, and H. Robenek, “Endocytosis of oxidized LDL and reversibility of migration inhibition in macrophage-derived foam cells in vitro. A mechanism for atherosclerosis regression?” Arteriosclerosis and Thrombosis, vol. 12, no. 8, pp. 936–944, 1992. View at Publisher · View at Google Scholar · View at Scopus
  39. J. L. Breslow, “Mouse models of atherosclerosis,” Science, vol. 272, no. 5262, pp. 685–688, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. R. L. Reddick, S. H. Zhang, and N. Maeda, “Atherosclerosis in mice lacking Apo E. Evaluation of lesional development and progression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 14, no. 1, pp. 141–147, 1994. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Zhu, W. G. Zhang, G. J. Zheng, and H. Jiang, “PPARγ with atherosclerosis and intervention study of traditional Chinese medicine,” Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, vol. 5, no. 3, pp. 225–227, 2007. View at Google Scholar